For the year ending 2025-12-31, MYNZ made $537,080 in revenue. -$16,279,741 in net income. Net profit margin of -3031.16%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue | 537,080 | |||
| Cost of revenue | 147,288 | |||
| Gross profit | 389,792 | |||
| Sales and marketing | 3,820,509 | |||
| Research and development | 4,905,791 | |||
| Research and development related party | 54,775 | |||
| General and administrative (note 2) | 5,107,535 | |||
| Impairment of intangible asset | 2,640,280 | |||
| Total operating expenses | 16,528,890 | |||
| Loss from operations | -16,139,098 | |||
| Other income | 42,180 | |||
| Government grant | 533,503 | |||
| Change in fair value of convertible debt | -21,000 | |||
| Gain (loss) on sales and disposal of assets | -163,248 | |||
| Interest expense | 373,458 | |||
| Other expense | 131,597 | |||
| Total other expense | -71,620 | |||
| Loss before income tax | -16,210,718 | |||
| Net loss | -16,210,718 | |||
| Foreign currency translation adjustment | -69,023 | |||
| Total comprehensive loss | -16,279,741 | |||
| Basic EPS | -2.7 | |||
| Diluted EPS | -2.7 | |||
| Basic Average Shares | 5,996,887 | |||
| Diluted Average Shares | 5,996,887 | |||
MAINZ BIOMED N.V. (MYNZ)
MAINZ BIOMED N.V. (MYNZ)